Thomas M. Wisniewski, MD

About Me

Conditions and Treatments

Alzheimer's disease, cognitive disorder, dementia, lewy body dementia, memory disorders, frontotemporal dementia, prion disease, Jakob-Creutzfeldt syndrome, memory loss, cognitive impairment


  • Lulu P. and David J. Levidow Professor of Neurology, Department of Neurology
  • Professor, Department of Pathology
  • Professor, Department of Psychiatry
  • Director, Alzheimer's Disease Center
  • Director, Center for Cognitive Neurology
  • Director, Pearl I. Barlow Center for Memory Evaluation and Treatment
  • Director, Division of Cognitive Neurology
  • Director, Neuropathology Fellowship
  • Assoc Chair for Research, Department of Neurology
Board Certifications
  • American Board of Pathology (Neuropathology), 1990
  • American Board of Psychiatry & Neurology - Neurology, 1989
Education and Training
  • Fellowship, Columbia Presbyterian Medical Center, Neuropathology, 1990
  • Residency, NYU Medical Center, 1988
  • MD from University Of London, 1983

Locations and Appointments

46 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP Medicare
  • HealthSmart (WTC)
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MultiPlan/PHCS PPO
  • NYS Empire Plan
  • Oscar
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • UPN Elite
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare Core and Charter
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Visiting Nurse Service (VNS) Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Pearl Barlow Center for Memory Evaluation and Treatment

145 East 32nd Street, 2nd Floor
New York, NY 10016

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Dr. Wisniewski obtained his MD at Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at NYU and Columbia-Presbyterian, respectively. He is a board certified Neurologist and Neuropathologist, who runs an active research laboratory focusing on neurodegenerative disorders, in particular the mechanisms which drive amyloid deposition in Alzheimer''s and prion related diseases. This work has led to over 240 peer-reviewed publications. An important aim of his work has been to direct this greater understanding toward therapeutic interventions. Key discoveries have included discovering the role of apolipoprotein E in driving amyloid deposition in late-onset AD. Dr. Wisniewski coined the term "pathological chaperone" to denote the role of apoE, even prior to the discovery of the linkage of apoE4 to late-onset AD. Dr. Wisniewski has also been developing strategies for the enhanced clearance of pathological conformations of both amyloid beta and tau proteins in AD using non-toxic, highly immunogenic proteins as "vaccines". This approach has been shown to be highly efficacious in several animal models of AD and prion diseases. He has also been working at using this immunomodulation approach for a broader list of neurodegenerative diseases, which are called "conformational disease". His work has shown that this approach delays the onset of disease in animal models of prion infection. Recent prion related studies have focused on testing a novel mucosal vaccine in white tailed deer to prevent chronic wasting disease (CWD). CWD is an emerging, highly infectious prion disease affecting large numbers of cervids in the USA and Canada. Recent data suggests mucosal vaccination can give partial protection from CWD.


  • Clearance systems in the brain-implications for Alzheimer diseaser

    Tarasoff-Conway, Jenna M; Carare, Roxana O; Osorio, Ricardo S; Glodzik, Lidia; Butler, Tracy; Fieremans, Els; Axel, Leon; Rusinek, Henry; Nicholson, Charles; Zlokovic, Berislav V; Frangione, Blas; Blennow, Kaj; Menard, Joel; Zetterberg, Henrik; Wisniewski, Thomas; de Leon, Mony J
    Nature reviews. Neurology. 2016 Apr. 12 (4): 248-248

  • Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors

    Cai, Tian-Quan; Stribling, Sloan; Tong, Xinchun; Xu, Ling; Wisniewski, Thomas; Fontenot, Jane A; Struthers, Mary; Akinsanya, Karen O
    Journal of pharmacological & toxicological methods. 2015 Jan-Feb. 71: 137-146

  • GATA1-mediated transcriptional regulation of the gamma-secretase activating protein increases Abeta formation in Down syndrome

    Chu, Jin; Wisniewski, Thomas; Pratico, Domenico
    Annals of neurology. 2015 Oct 29. 79 (1): 138-143

Read All Publications (376)